Kodiak Sciences Inc
Company Profile
Business description
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.
Contact
1250 Page Mill Road
Palo AltoCA94304
USAT: +1 650 281-0850
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
124
Stocks News & Analysis
stocks
Disney earnings: Experiences and streaming again drive excellent results
stocks
ASX utility share downgraded as electricity prices fall
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,445.10 | 33.80 | 0.36% |
| CAC 40 | 8,734.14 | 34.43 | 0.40% |
| DAX 40 | 26,373.40 | 233.27 | 0.89% |
| Dow JONES (US) | 54,044.44 | 159.34 | 0.30% |
| FTSE 100 | 10,917.91 | 50.02 | 0.46% |
| HKSE | 25,668.03 | 137.75 | 0.54% |
| NASDAQ | 26,641.99 | 293.64 | 1.11% |
| Nikkei 225 | 65,606.71 | 76.55 | -0.12% |
| NZX 50 Index | 13,824.13 | 133.93 | -0.96% |
| S&P 500 | 7,754.45 | 44.49 | 0.58% |
| S&P/ASX 200 | 9,263.60 | 34.80 | 0.38% |
| SSE Composite Index | 3,940.04 | 39.68 | 1.02% |